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Abstract – This study was aimed at characterizing the potential differences in gene expression in piglets
inoculated with Porcine circovirus type 2 (PCV2), the essential causative agent of postweaning multisystemic
wasting syndrome. Seven-day-old caesarean-derived, colostrum-deprived piglets were distributed into two
groups: control (n = 8) and pigs inoculated with 105.2 TCID50 of the Burgos PCV2 isolate (n = 16). One control
and three inoculated pigs were necropsied on days 1, 2, 5, and 8 post-infection (p.i.). The remaining pigs (four of
each group) were sequentially bled on days 0, 7, 14, 21, and 29 p.i. (necropsy). Total RNA from the mediastinal
lymph node (MLN) and lysed whole blood (LWB) samples were hybridized to Affymetrix Porcine GeneChip.
Forty-three probes were differentially expressed (DE) inMLN samples (FDR < 0.1, fold change > 2) and were
distributed into three clusters: globally down-regulated genes, and up-regulated genes at early (ﬁrst week p.i.)
and late (day 29 p.i.) stages of infection. In LWB samples, maximal differences were observed at day 7 p.i., with
54 probes DE between control and inoculated pigs. Main Gene Ontology biological processes assigned to up-
regulated genes were related to the immune response. Six common genes were found in both types of samples,
all of which belonged to the interferon signaling antiviral effector pathway. Down-regulated genes were mainly
related to cell adhesion and migration in MLN, and cellular organization and biogenesis in LWB. Microarray
results were validated by quantitative real-time PCR. This study provides, for the ﬁrst time, the characterization
of the early and late molecular events taking place in response to a subclinical PCV2 infection.
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1. INTRODUCTION
Porcine circovirus type 2 (PCV2) is a small
non-enveloped, single-stranded circular DNA
virus that has been identiﬁed as theprimary cause
of postweaning multisystemic wasting syn-
drome (PMWS). Typical PMWS clinical signs
are characterized by severe lost of weight
(wasting), pallor of skin, respiratory distress, and
jaundice, which mainly affect late nursery and
fattening pigs [16]. The hallmark microscopic
lesion of PMWS is moderate to severe lympho-
cyte depletion accompanied by histiocytic inﬁl-
tration in lymphoid tissues and granulomatous
inﬂammation in a variety of organs such as the
lungs, liver, kidney, heart, and intestines [3, 41].
Some experimental infections have been able
to reproduce the histopathological lesions
observed in naturallyPMWS-affected pigs; how-
ever, reproduction of disease has been limited to
a few experiments [44]. In many cases, PMWS
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development requires a trigger such as coinfec-
tion with other pathogens (porcine parvovirus
(PPV), porcine respiratory and reproductive syn-
drome virus (PRRSV), Mycoplasma hyopneu-
moniae, among others), or immune stimulation
of the host [44]. Host genetics may also affect
the outcome of PCV2 infection. In this sense, a
genetic predisposition to suffer from PMWS
has been pointed out since ﬁeld observations
and recent experimental studies identiﬁed certain
genetic lines of pigs that tended to bemore or less
susceptible to PCV2 infection [25, 26, 32, 33,
36]. In addition to breed susceptibility/resistance
to suffer from the disease, other individual
genetic factors may also be underlying the
observed differences in the ability of mounting
a good adaptive immune response between sus-
ceptible and diseased pigs [10, 20, 27, 28, 39].
The recent advent of microarray technology
has currently made available the determination
of the gene expression level of thousands of dif-
ferent genes at the same time, thus allowing the
proﬁling of the entire porcine transcriptome. This
technology has been successfully applied to the
study of the porcine immune response against
several swine pathogens such as Salmonella
[47, 50], Actinobacillus pleuropneumoniae
[17], PRRSV [14, 21, 22], and pseudorabies
virus [7, 8]. Previously, we performed an explor-
atorymicroarray studyusing lungandmesenteric
lymph node samples from PCV2-inoculated
Duroc pigs at 23 days p.i. (dpi) thereby identify-
ing several genes closely related to the immune
response such as cytokines,CD8, immunoglobu-
lin, and T cell receptor (TCR) alpha molecules
which were mostly up-regulated in the PCV2-
inoculated group [6].
The present work is aimed at characterizing
the early and late molecular mechanisms under-
lying the immune response of cesarean derived,
colostrum deprived (CDCD) piglets subclini-
cally infected with PCV2 using a genome-wide
expression approach. Mediastinal lymph node
(MLN) and peripheral blood RNA samples
were collected at ﬁve different time points,
and were hybridized to the Affymetrix 24K
Porcine Genechip1, which is a 25-oligomer
one channel chip that contains 24 123 probe-
sets, interrogating a total of 20 201 Sus scrofa
genes. This study gives new insights into the
knowledge of PCV2 host-pathogen interaction
and the mechanisms by which an effective
immune response occurs.
2. MATERIALS AND METHODS
2.1. Experimental design
All experimental procedures and animal care were
undertaken in accordance with the guidelines of the
Good Experimental Practices, under the supervision
of the Ethical and Animal Welfare Committee of
the Universitat Auto`noma de Barcelona.
Speciﬁcally, 24 seven-day-old, Landrace CDCD
piglets were used. The selection of Landrace pigs
was done due to the fact that this pig breed has
been shown to be more susceptible to suffer from
PMWS disease [32, 33]. A ﬁrst group of pigs
(n = 8) was kept as un-inoculated controls and the
rest of the pigs (n = 16) were oronasally inoculated
with 105.2 TCID50 of the Burgos isolate of PCV2
[11]. The piglets used in the present work belonged
to previous studies in which the virological, clinico-
pathological and immunological outcomes were
evaluated [5, 12]. Brieﬂy, all pigs remained clini-
cally healthy during the experimental period.
PCV2 subclinical infection was conﬁrmed in all
virus-inoculated pigs by quantitative real time
PCR (qPCR). The PCV2 genome was detected from
7 dpi to the end of the experimental period and all
pigs had seroconverted by the end of the study.
Microscopic examination revealed mild PMWS-like
lesions mostly in the MLN of almost all PCV2-
inoculated pigs. Control piglets remained free of
PCV2 infection throughout the experiment and no
histological lesions were detected.
One control pig and three inoculated pigs were
necropsied on days 1, 2, 5, and 8 post-inoculation
(p.i.). The remaining pigs (4 of each group) were fol-
lowed up throughout the experimental period, being
bled at days 0, 7, 14, 21, and 29 p.i. (Fig. 1). One
milliliter of whole blood samples were immediately
lysed (referred to as LWB) with nucleic acid puriﬁca-
tion lysis solution (Applied Biosystems, Warrington,
UK) and were immediately frozen at 96 C. At
necropsy (days 1, 2, 5, 8, and 29 p.i., Fig. 1), samples
of MLN were collected by immersion in liquid nitro-
gen for microarray studies. All collected samples
were kept at 80 C until usage.1 http://www.affymetrix.com
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2.2. RNA extraction and microarray
hybridization
Total RNA extraction from MLN and LWB sam-
ples was performed with the RiboPureTM kit (Ambion,
Austin, USA), following the manufacturer’s instruc-
tions. RNA quality was assessed with the RNA Nano
6000 Labchip kit on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, USA). RNA was
quantiﬁed using the NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington,
USA). Samples were hybridized to the Affymetrix
24K Genechip Porcine Genome Array (Affymetrix,
Santa Clara, CA, USA) following the standard
Affymetrix one-cycle protocol. Reverse transcription,
RNA labeling, cRNA ampliﬁcation, hybridization,
and scanning procedures were conducted at the
Affymetrix facilities available at the Institut de
Recerca Hospital Universitari Vall d’Hebron, Barce-
lona, Spain2. In total, 24 MLN samples (8 control
and 16 PCV2-inoculated) and 39 LWB samples (cor-
responding to 2 groups · 4 piglets/group · 5 time
points) were hybridized to microarrays. One sample
of a PCV2 inoculated pig at day 21 p.i. was discarded
due to low RNA quality.
2.3. Microarray data analysis
Raw data and statistical analyses were performed
with Bioconductor [15] implemented inR 2.6.03. Data
quality was assessed by the QC function implemented
in the simpleaffy package [49]. The Robust Multichip
Average (RMA, [19]) methodologywas used for array
normalization. The Empirical Bayes t-test statistic
implemented in the limma package [40] was used to
determine differential gene expressionbetween control
and inoculated pigs. For LWB, a comparison between
both groups was performed for each time point. For
MLN samples, where only one control pig was avail-
able at 1, 2, 5, and 8 dpi, the effect of timewas included
in the model as a ﬁxed effect. The threshold of signif-
icancewas set to a false discovery rate (FDR, [2]) of 0.1
and a minimum fold change of 2. Hierarchical cluster-
ingwas performedwithCluster 3.0 and JavaTreeView
1.1 software4, using the uncentered correlation coefﬁ-
cient and the average linkage method. Probes were
annotated based on the chip annotation provided by
Affymetrix (NetAffx), Tsai et al. [45], and the annota-
tion of Iowa State University5. However, some of the
probes were not coincident between different sources
and were, therefore, validated by screening the probe
nucleotide sequence available at NetAffx with the nr
84444Total
43333PCV2
41111Control
29 dpi8 dpi5 dpi2 dpi1 dpiGroup
0 dpi 7 dpi 21 dpi 29 dpi14 dpi
MLN samples
LWB samples
Figure 1. Experimental design. MLN: mediastinal lymph node, LWB: lysed whole blood.
2 http://www.ir.vhebron.net
3 http://cran.r-project.org/
4 www.rana.lbl.gov/Eisen/Software.htm
5 Tuggle C., personal communication.
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and EST databases available at NCBI using the Basic
Local Alignment Search Tool6. These probes that
could not be assigned to a known gene were not used
for functional analyses. The Database for Annotation,
Visualization and Integrated Discovery7 was used for
assessing functional proﬁles of genes based on theBio-
logical Processes (BP) category of Gene Ontology
(GO). The MetaCore platform8 was used to map bio-
logical processes to canonical pathways and to con-
struct gene interaction networks9.
2.4. Quantitative real-time PCR
Validation of porcine differentially expressed
(DE) transcripts was done by qPCR for ﬁve genes
(Interferon gamma, IFNG; Immunoglobulin gamma
chain constant region, IgG; lectin galactoside-binding
soluble 3, LGALS3; myxovirus (inﬂuenza virus)
resistance 1,Mx1; and 20,50-oligoadenylate synthetase
1, OAS1) for the MLN samples and one gene (OAS1)
for the LWB samples. The hypoxantine phosphoribo-
syltransferase (HPRT1) gene was used as a reference
housekeeping gene in the MLN samples. The beta-
actin gene (ACTB) was selected as a reference for
qPCR analyses in LWB samples due to the extremely
low expression of HPRT1 gene in blood. Porcine
speciﬁc primers were designed with the Primer
Express software (Applied Biosystems, Warrington,
UK). Primer sequences are shown in Table I. cDNA
synthesis was performed with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosys-
tems) using 1 lL of total RNA from MLN and
LWB. Real-time qPCR was performed in triplicate in
a 20 lL ﬁnal volume reaction containing 4 lL of a
1:20 dilution of the cDNA, 300 nM of each primer,
0.2 lM random hexamers, and 10 lL of Power
SYBR Green PCR Master Mix on an ABI Prism
H7000 (Applied Biosystems). The thermal proﬁle
consisted of a denaturalization step at 95 C for
10 min followed by 40 cycles at 95 C/15 s and
60 C/1 min. PCR efﬁciencies between target and
housekeeping genes were validated for their relative
quantiﬁcation following the comparative Ct method
described by Livak and Schmittgen [24]. Resulting
qPCR data were Log2 transformed and analyzed,
on a gene-by-gene basis, with the proc GLM method
of SAS software (Statistics, V 9.1; SAS Institute,
Inc., Cary, NC, USA) following the models used
for microarray data analysis. The signiﬁcance thresh-
old was set at a < 0.05.
3. RESULTS
3.1. Microarray analysis
The comparison of the gene expression level
between control and infected pigs in MLN sam-
ples revealed 43 DE probes (FDR < 0.1, Log2
fold change > 2, Tab. II). Gene expression
Table I. List of primers used for quantitative PCR analysis.
Name Sequence 50 ! 30 Amplicon size (bp) GenBank accession number
ACTB-F CGCCCAGCACGATGAAG 63 DQ845171
ACTB-R CCGATCCACACGGAGTACTTG
HPRT1-F TCATTATGCCGAGGATTTGGA 90 DQ136030
HPRT1-R CTCTTTCATCACATCTCGAGCAA
IgG-F CAAGAGCTACACCTGCAATGTCA 59 U03778-82
IgG-R CACGCTTGTCCACCTTGGT
MX1-F CCCCTCCATAGCCGAGATCT 55 DQ095779
MX1-R TGCCGACCTCCTGATGGTA
OAS1-F CTGTCGTTGGACGATGTATGCT 63 NM_214303
OAS1-R GCCGGGTCCAGAATCACA
LGALS3-F AACAATTCTGGGCACAGTAAAGC 71 NM_001097501
LGALS3-R CAACATCATTCCCCTTCTTGAAA
IFNG-F GAATGACTTCGAAAAGCTGATTAAAA 61 EU118363
IFNG-R TGGCTTTGCGCTGGATCT
6 BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi
7 DAVID 2008, http://david.abcc.ncifcrf.gov/home.
jsp
8 GeneGo Inc., http://www.genego.com
9 Data from this work is available at Gene Expres-
sion Omnibus database with accession number
GSE14758.
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differences varied with time and three differenti-
ated clusters were identiﬁed (Fig. 2A). One clus-
ter grouped eight probes that were globally
down-regulated, from day 2 p.i. to the end of
the study (cluster a). Among the up-regulated
probes, two patterns were identiﬁed (clusters b
and c). Cluster b grouped 23 probes that were
up-regulated at early time-points after infection
(5–8 dpi), while cluster c grouped 12 probes
up-regulated at later stages of infection (29 dpi).
Thirty-ﬁve out of 43 DE probes corresponded to
well annotated genes and were, therefore, used
for functional analyses. The 35 DE genes were
assigned to eight biological processes
(p < 0.05, Fig. 3A). Themost signiﬁcant biolog-
ical processes over-represented in theMLNdata-
set were mainly related to immune system
response, catabolic processes and apoptosis.
In LWB samples, maximal differences in
gene expression between control and PCV2-
inoculated pigs were found at 7 dpi (Tab. III).
Only three probes were found DE on day
21 p.i., two of them up-regulated (DEP domain
containing 1B, involved in the intracellular sig-
naling cascade, and DC2 protein, a membrane
component) and one down-regulated (Exportin
7, involved in protein export from the nucleus)
in PCV2-inoculated pigs. No signiﬁcant differ-
ences were found at any of the remaining
time-points. Among the 54 DE probes in LWB
Figure 2. Heat maps of the differentially expressed probes between control (C) and PCV2-inoculated (I)
pigs in (A) mediastinal lymph node, where a, b, and c, represent clusters for globally down-regulated
probes, and early and late up-regulated probes in the mediastinal lymph node dataset, respectively; and (B)
blood samples. Red represents up-regulation and green shows down-regulation for differentially expressed
genes (FDR < 0.1, fold change > 2.0). (A color version of this ﬁgure is available at: www.vetres.org.)
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samples at 7 dpi, 35 probes were up-regulated
and 19 probes were down-regulated in the
PCV2-inoculated group (Fig. 2B). DE probes
corresponded to 42 conﬁrmed unique genes.
Figure 3B shows the most signiﬁcant BP of
the LWB dataset, which were mainly related to
the immune system response, protein
metabolism and cellular organization and
biogenesis.
The comparison between MLN and LWB
datasets revealed six common DE genes
(OAS1, Mx1, ISG15, UBE2L6, RSAD2, and
H28). Both datasets were jointly analyzed with
the Pathway analysis option of the MetacoreTM
platform and revealed that the top scored map
(p < 0.0001) corresponded to the antiviral
action of interferons. A gene interaction network
could be constructed using the common gene set
as a starting point and allowing the entrance of
other DE genes, unique either to the MLN or
to the LWB datasets, which were proven to be
involved in the same pathway (Fig. 4).
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immune response
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Figure 3. Biological process GO categorization of the signiﬁcant differentially expressed genes between
control and PCV2-inoculated pigs in (A) mediastinal lymph node and (B) blood samples.
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3.2. Validation of microarray experiments by
quantitative PCR
To conﬁrm the DE genes in the microarray
experiment, ﬁve (IFNG, IgG, OAS1, Mx1,
LGALS3) and one (OAS1) genes were selected
for real-time qPCR validation in the MLN
and LWB datasets, respectively. Real-time
qPCR results are shown in Table IV. All qPCR
validated genes displayed signiﬁcant differ-
ences in gene expression between control and
PCV2-inoculated pigs and showed similar fold
changes as the ones obtained by the microarray
analysis (Tab. IV), thus indicating that the
microarray data was highly reliable.
4. DISCUSSION
The most important challenge for PCV2
researchers nowadays is the understanding of
PMWS pathogenesis. The reason why all ani-
mals become infected but only a small percent-
age develops the disease is a question that
remains unsolved. Several authors suggest that
the complex host-virus interaction and the ﬁnal
ability of the pig to mount an effective immune
response may be the key factors [28, 42, 46].
Here, the transcriptional proﬁle of CDCD pigs
subclinically infected with PCV2 in MLN and
LWB samples was characterized to gain insight
into the early and late molecular events taking
place during PCV2 infection.
Overall, three patterns of gene expression
were identiﬁed in MLN samples: globally
down-regulated genes, and up-regulated genes
at early and late stages of infection; whereas
in LWB samples DE genes were mostly identi-
ﬁed at day 7 p.i. Most down-regulated genes in
MLN encoded for molecules that participate in
cell adhesion and migration processes such as
LGALS3 [31], FBLN1 [43], TFPI [35], HMOX1
[1], and CXADR [9]. These gene products
mainly act as inhibitors of migration and cell
proliferation and, therefore, the sustained reduc-
tion in their expression, found from day 2 p.i.
onwards in all PCV2-inoculated pigs, may be
related to the inﬂammatory processes (granu-
lomatous inﬁltration) occurring in animals
suffering PMWS.
The ﬁrst days after PCV2 infection appeared
to be the moment in which a higher number of
genes were up-regulated both in MLN and
LWB samples. The vast majority of these up-
regulated genes were involved in a common
pathway, the interferon-mediated antiviral effec-
tor pathway. This result agrees well with the
fact that a peak of IFN-a was detected at day
5 p.i. in the PCV2-inoculated pigs from this
experiment [12]. However, differences in IFNA
gene expression in PCV2-inoculated pigs could
not be detected, probably due to the fact that its
expression took place in a different time point
to those herein analyzed. Activation of interfer-
ons in response to viral infection leads to the
Table IV. Results of the quantitative PCR validation of differentially expressed genes between PCV2-
inoculated and control pigs and comparison with microarray gene expression data.
Genes Quantitative PCR Microarrays
FC Log2 FC S.E. p value Probes FC Log2 FC p value
Mediastinal lymph node
IFNG 3.63 1.86 0.38 0.0001 Ssc.4093.1.A1_at 2.91 1.54 0.0086
IgG 2.93 1.55 0.44 0.0026 Ssc.11070.1.S1_at 2.19 1.13 0.0981
Ssc.13778.1.S1_at 2.22 1.15 0.0236
LGALS3 3.70 1.89 0.53 0.0023 Ssc.17815.1.S1_at 2.86 1.50 0.0086
Mx1 2.62 1.39 0.66 0.0501 Ssc.221.1.S1_at 2.67 1.41 0.0699
OAS1 3.92 1.97 0.69 0.0103 Ssc.1031.1.S1_at 3.53 1.82 0.0887
Blood (7 dpi)
OAS1 11.96 3.58 1.07 0.0156 Ssc.1031.1.S1_at 13.69 3.78 0.0039
FC: fold change, S.E.: standard error.
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activation of a cascade of intracellular signaling
events that, ultimately, induce the expression of
hundreds of genes, commonly known as inter-
feron stimulated genes (ISG). Most of these
ISG have been shown to display antiviral prop-
erties (for a review see [37]). The most promi-
nent interferon-mediated antiviral effectors
represented in the present study were OAS1,
Mx1, and ISG15. The OAS1 protein catalyzes
the synthesis of 20,50-oligomers of adenosine
that bind to and activate RNase L, which
degrades viral and cellular RNA, leading to
the inhibition of cellular protein synthesis and
impairment of viral replication [37]. Mx1
belongs to the dynamin superfamily of large
GTPases and has been shown to exert their anti-
viral function by binding viral essential compo-
nents, thereby blocking viral replication [37].
ISG15 has been recognized as an ubiquitin-like
protein [18]. Protein ubiquitylation implies the
post-translational labeling of a protein by cova-
lent attachment of an ubiquitin monomer for
its degradation in the proteasome. This mecha-
nism has been shown to exert a crucial role
in the regulation of immune response [34]. Sev-
eral ubiquitin (UBE2L6, HERC6, and USP18)
and proteasome (PSMF1) related enzymes
were up-regulated in PCV2-inoculated pigs.
Recently, it has been shown that the PCV2 open
reading frame (ORF) 3 interferes with porcine
ubiquitin E3 ligase Pirh2 [23]. The ubiquitin-
proteasome system plays a key role in host-
pathogen interactions and many viruses have
developed different immune evasion strategies
by altering this pathway [13]. The activation
of several ubiquitin-proteasome related genes
in PCV2 subclinically infected pigs may indi-
cate that this pathway is crucial for the control
of PCV2 pathogenesis. Other interferon-induc-
ible genes found differentially regulated either
in MLN or LWB datasets were RSAD2, H28,
IFI44L, ISG20, GBP1, GBP2, and IFI6. Over-
all, these results indicate that an effective activa-
tion of the immune response was produced
early (ﬁrst week) after infection with PCV2 in
lymph nodes (at least in the MLN), which is
also reﬂected in blood samples, where a number
of genes directly related to the activation of the
immune system were also found up-regulated
(TCRA, CCL5, CD2, CD74, and SYK).
In LWB samples at 7 dpi, several genes
implicated in the organization and biogenesis
of cellular components were DE between con-
trol and PCV2-inoculated pigs, such as the
members of the Rab (RAB11A and RAB38)
and Rho (RAC2, ARHGDIB, and ARHGP6)
small GTPases, and the clathrin-associated
adaptor complexes (AP1S2 and AP2S1). These
genes appeared mostly down-regulated except
for AP2S1 and ARHGDIB transcripts, which
were up-regulated. These genes have been
shown to participate in endocytosis-related pro-
cesses. PCV2 internalization is produced by
endocytosis, mainly through actin and
Rho-GTPase mediated, dynamin-independent
pathways [29, 30]. Furthermore, antigen (Ag)
presentation by professional antigen presenting
cells involves an active uptake of superﬁcial
Ag through macropinocytosis and/or phagocy-
tosis processes followed by a complete arrest
of this process to Ag processing and presenta-
tion to T cells in secondary lymphoid organs
[4, 38, 48]. The fact that some of these genes
were up-regulated while others were down-reg-
ulated might be explained by the fact that a mix-
ture of cells at different stages can be found in
LWB, and both processes (virus internalization
and Ag presentation) can occur simultaneously.
In late stages of infection, a relatively low
number of DE probes were found compared
to the results reported by [6]. In that experi-
ment, different pig breed, tissue samples, nec-
ropsy days, and statistical analysis were used,
which may explain the differences found
between both experiments. However, an
increase of certain cytokines (CCL4L, CXCL9,
and CXCL11 in [6], and IFNG in the present
work) and IgG mRNA was detected in PCV2-
inoculated pigs from both studies, thus indicat-
ing that similar immunological responses
against PCV2 were obtained in Duroc [6] and
Landrace (this study) subclinically infected
pigs. Furthermore, the expression of IFNG
and IgG genes in MLN samples correlated well
with the immunological results obtained by [12]
using animal material from the present experi-
ment. In this work, a peak of IFN-c was
detected between days 14 and 21 p.i. and sero-
conversion took place between days 7 and 14
p.i. in all PCV2-inoculated pigs. In the current
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experiment, expression of IFNG gene started
increasing from day 8 p.i. and was mainly
over-expressed in pigs infected with PCV2 at
day 29 p.i., which agrees well with its role in
the early immune response against viruses.
A relatively low number of DE probes were
found for both MLN and LWB datasets. This
may probably be due to two main reasons. First,
tissues are heterogeneous, composed by a mix-
ture of different cell types, each with a speciﬁc
transcriptional proﬁle. Second, the low number
of samples used for microarray analyses may
increase data variability and reduce the statistical
power to detect DE genes. This aspect might be
the case for the analyses of MLN samples, since
only one control pigwas used for each timepoint.
Overall, this study has allowed the character-
ization, for the ﬁrst time, of the genes that are
involved in the molecular events underlying
an effective immune response to counteract an
infection with PCV2 and, more importantly, to
control disease progression. The results from
this study provide new insights into the com-
plex host-PCV2 interaction, from a subclinical
point of view. Given the difﬁculties in repro-
ducing PMWS disease experimentally, further
studies should be performed in healthy and nat-
urally PMWS-affected pigs to explore the host-
virus molecular interactions upon disease status.
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